industry pr

Press release news from the public relations clients of Tiziani Whitmyre, Inc.

Posts Tagged ‘Manufacturing’


Friday, April 19th, 2013

Microbiology Quality Control Seminar to Assist Medical Device Manufacturers Validate Sterilization, Cleaning Processes

A seminar on microbiology quality control — designed to help medical device manufacturers validate sterilization and cleaning processes, and maintain controlled environments — will be held on Thursday, May 16, in Boston.

“For today’s medical device manufacturers, the challenge is to validate their sterilization and cleaning processes to ensure patient safety and product integrity. This seminar will focus on a host of issues pertaining to the sterilization of medical devices including sterilization validation, bioburden, sterility, and endotoxin testing, as well as submitting samples to a contract testing laboratory,” said Steven Richter, Ph.D., president and scientific director of Microtest Laboratories, which is hosting the event.

Topics at the “Microbiology Quality Control Seminar” will include:

  • MICRO 101
  • Sterilization Validation
  • Bioburden Testing
  • Sterility Testing
  • Endotoxin Testing
  • Testing Sample Submissions

The event will be held at the MIT Endicott House in Boston, Mass., on Thursday, May 16, 2013, from 9 a.m. to 3:30 p.m. Registration is 9 a.m. to 9:45 a.m. A networking reception and lunch are included.

To register, download the form from http://www.microtestlabs.com/pdfs/seminar-registration-form_1305.pdf. Or, contact Julie Adamski at Microtest Laboratories by phone at 1-800-631-1680, ext. 192, or by email at jadamski@microtestlabs.com. The registration fee is $149.

The event is one in a series of technical seminars and workshops for medical device and pharmaceutical manufacturers presented by Microtest Laboratories, a Mass.-based, FDA-audited company with a history of exceptional regulatory compliance.

About Microtest Laboratories

Microtest Laboratories is a leader in testing services and contract manufacturing for the medical device, pharmaceutical, and biotechnology industries. Based in Agawam, Massachusetts, USA, the company provides expertise and flexible processes that enhance product safety and security, accelerate time to market, and minimize supply chain disruption. For more information, visit http://www.microtestlabs.com or call 1-413-786-1680 or toll-free 1-800-631-1680. Follow Microtest Laboratories on Twitter @MicrotestLabs at http://twitter.com/MicrotestLabs.

Tags: , , , , , , , , ,
Posted in Health/Medical, Manufacturing |


Tuesday, September 18th, 2012

Cost-Efficient Manufacturing Practices for Military and Aerospace Products Are Outlined in New Management Brief

CRANSTON, RI — Sept. 18 , 2012 — By adopting best practices from non-military markets, and adapting them to defense and aerospace applications, military original equipment manufacturers (OEMs) can accelerate the reengineering process and reduce the time it takes to realize the cost reduction benefits, according to a new management brief available to download from Federal Electronics at http://www.federalelec.com/militarybrief.

Outsourcing of manufactured products at all levels has been an integral part of commercial and industrial OEM supply chain strategies for literally decades. But only recently has it gained traction with military contractors. To avoid an array of issues that may hamper outsourcing efforts, the brief, titled, “Cost-Efficient Manufacturing for Military and Aerospace Products,” recommends a series of common practices that promote cost efficiency and process agility. They include:

  • Establishing outsourced product transfer procedures that build upon the current state of the manufacturing process.
  • Implementing product/process documentation programs that promote collaboration in the supply chain.
  • Opening reviews of new designs to key suppliers as early in the design phase as possible.
  • Identifying non-critical, high-labor content elements of the product and introducing low-cost region manufacturing into the supply chain.
  • Selecting an EMS provider who straddles the line between military and industrial applications.
  • Accentuating current supply chain staffs with individuals whose skill sets were honed in the commercial, industrial, and medical environments.

According to the brief, prime contractors, tasked with wringing costs and delays out of their product development and fulfillment processes, will continue to harvest proven, best-in-class practices from non-military OEMs. Expanding the use of outsourcing methodologies with a properly aligned and sized supply chain will provide significant opportunity to achieve the levels of cost reduction and business process acceleration that are required to support defense and aerospace customers in the future, the brief states.

Download the new management brief, “Cost-Efficient Manufacturing for Military and Aerospace Products,” from http://www.federalelec.com/militarybrief.

About Federal Electronics

Founded in 1948, Federal Electronics, Inc., is a leading vertically-integrated electronics manufacturing services (EMS) provider. Service offerings include advanced technology circuit card assembly, cable and wire harness assembly, fiber optic interconnect assembly and functionally tested higher level assemblies and system level integration. Based in Cranston, Rhode Island, and Hermosillo, Mexico, the electronics contract manufacturer serves the needs of military prime contractors and original equipment manufacturers by providing comprehensive production solutions that lower cycle times, control and reduce costs, and create flexible supply chains that are responsive to volume variability. For more information, visit http://www.federalelec.com.

Tags: , , , , , , , , , ,
Posted in Manufacturing |


Tuesday, July 24th, 2012

New White Paper, “Five Biggest Myths about Medical Products Outsourcing,” Finds OEM’s Concerns are Often Unfounded

BILLERICA, MA — July 24 2012 — A new white paper, “The Five Biggest Myths about Medical Products Outsourcing,” examines the reasons why five typical areas of concern about outsourcing medical products manufacturing are often unfounded. In addition, the paper outlines the advantages that outsourcing can provide original equipment manufacturers (OEMs) in terms of delivering quality products on time and on budget. The paper is available now for download at http://resources.labmedical.com/medical-products-outsourcing from LAB Medical Manufacturing.

Outsourcing medical product manufacturing is a thriving industry. In the U.S. alone, more than 3,000 firms offer their services as a contract manufacturer (CM) for medical devices, instruments, and implants. Most leading original equipment manufacturers (OEMs) of medical products employ at least some CMs; many have made them permanent parts of their manufacturing resource strategy.

However, some OEM planners resist using CMs, or have difficulty selecting the right one.

The white paper, titled “The Five Biggest Myths about Medical Products Outsourcing,” discusses the five top myths about outsourcing medical product manufacturing that lure OEMs into falling prey to misunderstandings or concerns. These include cost, quality, or product complexity, or about maintaining control of intellectual property, or feel insecure about utilizing any but the very largest CMs.

The five myths are:

  • Myth #1: The lowest purchase price equals the lowest cost.
  • Myth #2: Every source offers the same quality.
  • Myth #3: You can only outsource the simple stuff.
  • Myth #4: Outsourcing equals losing control.
  • Myth #5: Size matters most.

OEMs may entertain several fears that make them reluctant to use new contract manufacturers, or indeed to employ CMs at all, according to the white paper. However, the right CM, with the relevant resources and with experience in a given product type, can often be a good fit to an OEMs’ requirements.

A nimble, right-sized CM can offer a fruitful collaboration that produces improved medical instruments and implants — on time and on budget — to achieve enhanced patient outcomes, the white paper reports.

Download the new white paper, “The Five Biggest Myths about Medical Products Outsourcing,” from http://resources.labmedical.com/medical-products-outsourcing.

About LAB Medical Manufacturing

LAB Medical Manufacturing, Inc., is a world-class contract manufacturer of high-precision medical devices and implants for leading original equipment manufacturers (OEMs). Its high-quality, cost-effective solutions help achieve better patient outcomes while reducing health care expenses. Founded in 1984, the company combines a passion for problem-solving with comprehensive in-house resources; exceptional engineering; unmatched application expertise; and flexible, integrated manufacturing. It is ISO 13485:2003 certified and FDA registered as a contract manufacturer. LAB Medical maintains facilities in Billerica, Massachusetts, USA, and Nowa Deba, Poland. Visit the company website at http://www.labmedical.com.

Tags: , , , ,
Posted in Health/Medical, Life Sciences |


Wednesday, May 30th, 2012

Clean Room Environmental Best Practices for Medical Device & Pharmaceutical Manufacturers are Focus of Boston Seminar on June 6

AGAWAM, MASS. – May 30, 2012 – Sterile manufacturing environments at medical device and pharmaceutical companies require effective cleaning and disinfection programs to maintain aseptic conditions and prevent microbial contamination. To help, laboratory testing experts will present “Clean Room Environmental Best Practices,” a special seminar in Boston on Wednesday, June 6, 2012.

The seminar is designed for all professionals responsible for building, validating, and maintaining controlled environments in the medical device and pharmaceutical industries. The program will include technical presentations on:

• Best practices for qualifying and maintaining clean room facilities

• “The people factor” in terms of containment control

• Qualifying and evaluating clean room disinfectants

• Difficult challenges: Practical advice and solutions

Opportunities for questions and continuing interaction will be encouraged.

“Clean Room Environmental Best Practices” is scheduled for 10 a.m. to 2 p.m. on Wednesday, June 6, 2012, at the MIT Endicott House, 80 Haven Street, Dedham, Massachusetts — located just minutes from Boston. The cost is $149. Breakfast, lunch, and networking opportunities are included.

The seminar is sponsored by Microtest Laboratories, a Massachusetts-based, FDA-audited company with a history of exceptional regulatory compliance. Microtest’s environmental sciences group helps its clients maintain control of their controlled environments and is a proven resource for contamination testing needs arising from the manufacturing of medical devices or pharmaceuticals, as well as sterile compounding in hospital pharmacies.

For more information, contact Julie Adamski, toll-free, at 1-800-631-1680, ext. 192, or jadamski@microtestlabs.com.

About Microtest Laboratories

Microtest Laboratories is a leader in testing services and contract manufacturing for the medical device, pharmaceutical, and biotechnology industries. Based in Agawam, Massachusetts, USA, the company provides expertise and flexible processes that enhance product safety and security, accelerate time to market, and minimize supply chain disruption. For more information, visit http://www.microtestlabs.com or call 1-413-786-1680 or toll-free 1-800-631-1680. Follow Microtest Laboratories on Twitter @MicrotestLabs at http://twitter.com/MicrotestLabs.

Tags: , , , , , , , , ,
Posted in Biosciences, Health/Medical, Manufacturing |


Monday, April 2nd, 2012

“Proposed Changes to 21CFR 610: The New Scope of Biologics Sterility Testing” is Subject of New Management Brief

AGAWAM, MASS. – April 4, 2012 – The new scope of biologics sterility testing, resulting from the U.S. Food and Drug Administration’s (FDA) proposed changes to 21 CFR 610, is discussed in a new management brief from Microtest Laboratories. Download the brief from http://www.microtestlabs.com/21-cfr-610-paper.

The FDA’s proposed amendments to 21 CFR Parts 600, 610, and 680, published in the Federal Register on June 21, 2011, for review and comment, are focused on expanding the scope of the current sections to allow for greater flexibility in testing methodology.

“Through these changes, the FDA is embracing the emergence of new non-culture based technologies. If approved, they will provide the opportunity to utilize these methods as alternatives to culture-based sterility tests,” explains James E.T. Gebo, B.S., M.P.A., RM (NRCM), Technical Representative, Laboratory Services, Microtest Laboratories, in the brief, “Proposed Changes to 21CFR 610: The New Scope of Biologics Sterility Testing.”

“The most significant proposed revision is the elimination of the specified sterility test methods,” writes Gebo. “But while the proposed changes seem extreme at first glance, in the grand scheme they are beneficial for all interested parties.”

The brief discusses the potential benefits, including the opportunity for manufacturers and quality control laboratories to streamline their testing and adopt new emerging sterility test technologies — such as rapid testing methods employing PCR — that will further support the drive to achieve quicker product release.

Download the new free management brief, “Proposed Changes to 21CFR 610: The New Scope of Biologics Sterility Testing,” at http://www.microtestlabs.com/21-cfr-610-paper.

About Microtest

Microtest is a leader in testing services and contract manufacturing for the medical device, pharmaceutical, and biotechnology industries. Based in Agawam, Massachusetts, U.S.A., the company’s expertise and flexible processes enhance product safety and security, accelerate time to market, and minimize supply chain disruption. For more information, visit http://www.microtestlabs.com or call 1-413-786-1680 or toll-free 1-800-631-1680. Follow Microtest Labs on Twitter @MicrotestLabs at http://twitter.com/MicrotestLabs.

Tags: , , , , , , , ,
Posted in Health/Medical, Manufacturing |


Tuesday, February 14th, 2012

White paper Details New Medical Device Polymer Biocompatibility Screening Test Using Zebrafish Embryos

AGAWAM, MASS. – February 13, 2012 – A new white paper detailing the new ZET™ medical device polymer biocompatibility screening test using Zebrafish embryos is available to download from Microtest Laboratories at http://www.microtestlabs.com/zebrafish-test-paper.

The new ZET test was developed by Microtest Laboratories for medical device manufacturers and biomaterials researchers. It utilizes Zebrafish (Danio rerio) to screen plastics, composites, and polymers for toxicity.

“Zebrafish are extensively used in drug development studies due to their transparent embryos and fast development times,” writes white paper author Steven Richter, Ph.D., president and scientific director of Microtest Laboratories — and former FDA official. “The Zebrafish test demonstrates similarities to mammalian models and humans. Its unique approach to fast-track medical device toxicity screens will save manufacturers time and reduce expenses.”

In the new white paper, “New Medical Device Polymer Biocompatibility Screening Test Using Zebrafish Embryos (Danio Rerio),” Richter discusses U.S. Food and Drug Administration (FDA) testing requirements to assess medical device toxicology and describes which situations may trigger the need for manufacturers to repeat testing or undertake new programs.

Richter also provides background facts about Zebrafish and details the company’s testing that revealed ZET sensitivity is greater than USP gold standard test for BPA. In addition, he outlines the benefits of ZET versus USP cytotoxicity testing and ZET versus mouse embryo toxicity tests.

Download the white paper, “New Medical Device Polymer Biocompatibility Screening Test Using Zebrafish Embryos (Danio Rerio),” fromhttp://www.microtestlabs.com/zebrafish-test-paper.

About Microtest Laboratories

Microtest Laboratories is a leader in testing services and contract manufacturing for the medical device, pharmaceutical, and biotechnology industries. Based in Agawam, Massachusetts, U.S.A., the company provides expertise and flexible processes that enhance product safety and security, accelerate time to market, and minimize supply chain disruption. For more information, visit http://www.microtestlabs.com or call 1-413-786-1680 or toll-free 1-800-631-1680. Follow Microtest Laboratories on Twitter@MicrotestLabs at http://twitter.com/MicrotestLabs.

# # #

Press Contact: Don Goncalves, Tiziani Whitmyre public relations, 781-793-9380, dgoncalves@tizinc.com

Download high resolution image from: http://microtestlabs.com/photos

 


 

 

 

 

 

 

 

 

 

 

 

 

Tags: , , , , ,
Posted in Health/Medical, Life Sciences, Manufacturing |


Monday, September 26th, 2011

Fluid Automation: Unsung Contributor to Plant Economic Performance — New Management Brief from ASCO Numatics

FLORHAM PARK, N.J. — Sept. 26, 2011 — While fluid automation products — valves, pneumatics actuators, and similar components — control the flow of a process liquid or a supply of compressed air, they can also help control the flow of profits, according to a new management brief from ASCO Numatics.  Titled “Fluid Automation: The Unsung Contributor to Plant Economic Performance,” the brief is available for download at http://goo.gl/9MMkH.

The speed and reliability of fluid control products can provide competitive economic advantages in industrial operations worldwide. This is due to their ability to extend overall equipment service life, reduce warranty costs, cut maintenance/repair/operations (MRO) inventories, and increase production uptime and productivity.

But the choice of fluid automation technology is critical. For end users, judicious selection of fluid automation components must play a key role in their performance improvement plans. For original equipment manufacturers (OEMs), the right fluid automation choices provide significant cost, time-to-market, and product competitive advantages.

The new management brief examines available solutions and discusses how they  have maximized both speed and reliability — and provided surprisingly strong contributions to the economic performance of industrial operations.

The contents of the brief include:

  • Changing the Rhythm
  • Feeding the Bottom Line
  • The Benefits of Reliability
  • The Power of Speeds
  • Advantages for the OEM
  • Advances for the End User

Download the new management brief, “Fluid Automation: The Unsung Contributor to Plant Economic Performance,” from http://goo.gl/9MMkH.

Follow ASCO Valve on Twitter at http://twitter.com/ascovalve and on Facebook at http://www.facebook.com/ascovalve.

About ASCO Numatics

ASCO Numatics, a division of Emerson, offers comprehensive fluid automation solutions, including fluid control and fluid power products, for a wide range of industry-focused applications. The ASCO Numatics product line in North America consists of more than 50,000 valves, an extensive selection of air preparation equipment, and a full line of actuation products. ASCO products include solenoid pilot valves, angle body piston valves, linear indicators, redundant control systems, and pressure sensors. The Numatics line covers valve manifolds, cylinders, grippers, filters, regulators, and lubricators. For more information about ASCO Numatics products, visit www.asconumatics.com

About Emerson

Emerson (NYSE: EMR), based in St. Louis, Missouri (USA), is a global leader in bringing technology and engineering together to provide innovative solutions for customers in industrial, commercial, and consumer markets through its network power, process management, industrial automation, climate technologies, and tools and storage businesses. Sales in fiscal 2010 were $21 billion. For more information, visit www.Emerson.com.

# # #

Press Contact: Don Goncalves, 781-793-9380, dgoncalves@tizinc.com

 

Tags: , , , , , ,
Posted in Manufacturing, Technology |


Tuesday, July 13th, 2010

New White Paper Helps Medical Device Manufacturers Apply New FDA Regs to Combination Products

microtest-logo1

AGAWAM, MASS. – July 13, 2010 – A new free, white paper that guides medical device manufacturers in the complicated process of applying new U.S. Food and Drug Administration (FDA) regulations to combination products embedded with pharmaceutical or biologic components is now available from Microtest Laboratories (http://www.microtestlabs.com/combination-products-20/).wpcover1

Combination products are a large and growing segment of the medical device market, with some analysts estimating they represent over 30% of all new product submissions to the FDA. As the market continues to grow, it is further compounded by the introduction of human tissue and cellular products (HCT/Ps) incorporated in combination products, which in turn, raise a host of new challenges for testing, sterilization, and contamination avoidance.

Over the past 12 months, the FDA has addressed the dichotomy of dual quality systems by developing streamlined regulations for Good Manufacturing Compliance. These regulations, designated as 21 CFR Part IV, are anticipated to become law by the end of 2010.

Once promulgated, manufacturers will be held accountable for compliance and the FDA will use it as a legal document for enforcement. In the new white paper titled, “Combination Products 2.0: Applying the New FDA Regulations,” Steven Richter, Ph.D, President and Chief Scientific Officer of Microtest Laboratories, Inc., addresses the implications for manufacturers. (Download from: http://www.microtestlabs.com/combination-products-20/). In the white paper, Dr. Richter discusses:

  • The New Regulations
  • Determining Principal Mode of Action — Device or Drug?
  • Stem Cells & Human Tissue in Combination Products
  • The Implications for Testing and Validation
  • An Example: Drug-Eluting Stents

“The new FDA regulations governing combination products are a major step forward for the industry. They apply to parts of both the QSR and GMP quality systems in a way that makes sense for the unique characteristics of each combination product. 21 CFR Part IV closes the gaps in the 2004 guidelines and succinctly clarifies the process for establishing quality systems that ensure compliance and patient health and safety. The ability of manufacturers to understand, establish, implement reliable testing procedures will be critical in complying with these new requirements,” Dr. Richter said.

Download a free copy of “Combination Products 2.0: Applying the New FDA Regulations” from http://www.microtestlabs.com/combination-products-20/.

Dr. Richter founded Microtest in 1984 after a distinguished career at the U.S. Food & Drug Administration. Under his leadership, Microtest provides the medical device, pharmaceutical, and biotechnology industries with premier testing and manufacturing support.

Follow Microtest Labs on Twitter @MicrotestLabs at http://twitter.com/MicrotestLabs.

About Microtest
Microtest is a leader in testing services and contract manufacturing for the medical device, pharmaceutical, and biotechnology industries. Based in Agawam, Massachusetts, U.S.A., the company’s expertise and flexible processes enhance product safety and security, accelerate time to market, and minimize supply chain disruption. For more information, visit http://www.microtestlabs.com or call 1-413-786-1680 or toll-free 1-800-631-1680.

# # #

Public Relations contact, Boston:  Don Goncalves, dgoncalves@tizinc.com, 781-793-9380, for Tiziani Whitmyre Inc., http://www.tizinc.com/public-relations

Tags: , , , , , , , , , ,
Posted in Biosciences, Health/Medical, Manufacturing |


Friday, April 30th, 2010

Microtest Labs Provides Complete Fill and Finish Manufacturing Services for Clinical Trial Material

microtest-logo1

AGAWAM, MASS. – May 3, 2010 – Microtest Laboratories will highlight its newly expanded fill and finish manufacturing service for all Phases of clinical trials at the BIO International Convention, booth #1944, May 3-6 in Chicago.

Microtest is a leader in providing flexible, customizable aseptic processing and fill/finish services for all pharmaceutical producers conducting Phase 1, 2, or 3 clinical trials.

“Virtual companies and smaller pharma manufacturers with no infrastructure for manufacture can partner with Microtest to provide their clinical trial material to clinics in an efficient and timely manner. Large manufacturers that don’t wish to divert high-capacity production lines will find Microtest a fast, efficient, cost-effective alternative,” said Alex Mello, Director of Project Management, Microtest. “Manufacturers of any size will discover a partner in Microtest with all the specialized knowledge, experience, and facilities they need.”

Microtest provides the flexibility for all types of pharmaceutical and biopharmaceutical manufacturing. Microtest will formulate per the approved batch record, which may include mixing, agitation, heating/cooling, etc. Microtest can provide problem solving experience to any of the specifics of a manufacturer’s process. Post formulation, Microtest’s analytical capabilities allow for a full spectrum of available in-process tests to ensure that the drug product is formulated to the strict specifications set by the manufacturer. Post in-process testing, filtration occurs utilizing the manufacturer’s specified filtration system, redundant as applicable. The product is filled into the designated vial type/size specified by the manufacturer as well as stoppered and capped using the manufacturer defined container closure system. Product is filled, capped and sealed under an ISO Class 5 environmental area.

Post fill, the product undergoes full 100% manual visual inspection, which is quality-controlled post-inspection by a qualified operator by performing an AQL inspection. Product is labeled per approved labels and stored in Microtest’s fully validated material control department at a multitude of storage conditions.

“As Microtest is a leader in testing of pharmaceutical drug products, we offer the full release package on-site thereby ensuring the most expeditious release of the product,” Mello said. “The specification documents allow for maximum efficiency when the samples are taken and released to our QC laboratories – both QC Microbiology and QC Analytical. Our representatives can discuss the testing on any final drug product specification and determine the most efficient release strategy.”

Microtest fill/finish operations comply with both U.S. FDA and European EMEA guidelines. Microtest has been inspected by the U.S. FDA, U.S. DEA, and Qualified Persons (QP) for both the manufacture and release testing of final drug product.

For more information, visit Microtest at the BIO International Convention, booth #1944, May 3-6 in Chicago. Or, visit the Microtest website at: http://www.microtestlabs.com/aseptic-processing/fill-finish/ or call 1-800-631-1680. Follow Microtest Labs on Twitter @MicrotestLabs at http://twitter.com/MicrotestLabs.

About Microtest
Microtest is a leader in testing services and contract manufacturing for the medical device, pharmaceutical, and biotechnology industries. Based in Agawam, Massachusetts, U.S.A., the company’s expertise and flexible processes enhance product safety and security, accelerate time to market, and minimize supply chain disruption. For more information, visit http://www.microtestlabs.com or call 1-413-786-1680 or toll-free 1-800-631-1680.

# # #

Public Relations contact, Boston:

Don Goncalves, dgoncalves@tizinc.com, 781-793-9380, for Tiziani Whitmyre Inc., http://www.tizinc.com/public-relations

Tags: , , , , , , , , , ,
Posted in Biosciences, Health/Medical |


Tuesday, June 3rd, 2008

Microtest Labs Doubles Microbial Identification, Analytical Services

AGAWAM, MASS. – June 3, 2008 – Microtest Laboratories (http://www.microtestlabs.com/) has doubled their microbial identification and analytical services with the purchase of an additional MicroSeq® Microbial Identification System.

The MicroSeq is a state-of-the-art DNA sequence-based system that enables Microtest technicians to more quickly and accurately identify bacteria isolates that are not viable or easily identified.

“With the purchase of our second MicroSeq system, we are not only complimenting our existing unit but doubling our analytical capacity and ability to service our clients,” stated Dr. Steven Richter, Microtest President and Chief Scientific Officer. “As one of the only testing labs in the area with this technology, we are providing our customers with a significant competitive advantage.”

Using the MicroSeq system, Microtest technicians can provide precise and reliable bacteria, mycoplasma, and mold identification in a 24-hour time period. Traditional bacteria and mold identification lab tests are often less accurate, and require up to a one-week turn around time.

“In the highly competitive biotechnology industry, accuracy and speed cannot be compromised,” stated Dr. Richter. “Our ability to provide rapid identification helps our customers minimize down-time, which directly affects their bottom-line. When manufacturing is halted or a cleanroom is shut-down and awaiting test results, there is no product going out the door and that translates to an interruption in sales.”

The MicroSeq system is integrated for use across the spectrum of services that Microtest provides. Customers that will benefit most are those that utilize their analytical testing services in:

  • Contract Manufacturing
  • Pharmaceutical Testing & Validation
  • Medical Device Testing & Validation
  • Environmental Control and Testing
  • Water Validation
  • Mold Identification
  • Biologics/Virology

The MicroSeq systems are 99% reliable with repeatable results, and is especially beneficial for companies with pharmaceutical and medical device manufacturing applications. Made by the Applera Corporation, the MicroSeq Microbial Identification System is the most accurate and rapid bacterial identification system available today.

For more information about Microtest’s analytical testing and related services, visit contact the Microtest on the Web at: www.microtestlabs.com/medical-device-testing or by phone 1-800-631-1680.

About Microtest
Microtest is a leader in testing services and contract manufacturing for the medical device, pharmaceutical, and biotechnology industries. Based in Agawam, Massachusetts, USA, the company’s expertise and flexible processes enhance product safety and security, accelerate time to market, and minimize supply chain disruption. For more information, visit www.microtestlabs.com or call 1-413-786-1680 or toll-free 1-800-631-1680.

# # #

Public Relations contact: Tiziani Whitmyre Inc.

Technorati tags: , , , , , , ,

Tags: , , , , , , , , , ,
Posted in Biosciences |

« Older Entries

Industry PR is proudly powered by WordPress.
WordPress